← All devices 
Clinical / medical-grade · Implant · by Senseonics
Eversense E3
The 180-day implantable CGM — PMA-approved and accurate, but with surgical insertion and twice-daily calibration.
February 2022Eversense E3
Late in cycle4 yr 4 mo old
Superseded by the year-long Eversense 365 (FDA-approved 2024).
API access: Yes — open Raw data access: Yes — open Open source: No public repo
Clinical value
84/100
PMA-approved 180-day CGM
Empowerment
55/100
Open sharing, surgical/Rx friction
Everyday value
48/100
6-month sensor, heavier calibration
The 180-day implantable CGM and predecessor to the Eversense 365 — PMA-approved and accurate, with broad third-party sharing, but requiring in-office surgical insertion and (especially early in wear) twice-daily calibration.
What it measures
Fully implantable fluorescence glucose sensor (under the upper-arm skin) with a removable on-skin transmitter; continuous glucose with alerts and on-body vibration alarms.
Regulatory status
FDA PMA approval (Feb 2022) — the highest FDA bar; 180-day wear, adults, prescription. Predecessor to the year-long Eversense 365.
Validation & accuracy
PROMISE study MARD ~8.5–9.1%; accurate, but requires two fingerstick calibrations per day for the first 21 days, then daily.
Data control & export
Raw data: open — app shares to Apple Health and care team, with Glooko/Tidepool integrations. API: open (third-party integrations).
Wearability & battery
A 6-month implanted sensor plus a removable on-skin transmitter; surgical insertion/removal and frequent early calibration add friction.
Cost & access
Prescription; in-office insertion/removal; most insurers and Medicare cover part.
Who it serves
People who want a long-duration implanted CGM with strong data sharing.
Who is left out or burdened
Surgical insertion, heavier calibration than the 365, and prescription gatekeeping.
✓ Strengths
- PMA-approved 180-day implantable CGM
- Broad sharing (Tidepool, Glooko, Apple Health)
- On-body vibration alerts without a phone
- Accurate (MARD ~8.5–9.1%)
✕ Weaknesses
- Surgical insertion/removal by a provider
- Twice-daily calibration early in wear
- Prescription-only; proprietary transmitter
- Superseded by the year-long Eversense 365
84
Why this clinical score. PMA approval and a validated 6-month sensor are clinically top-tier; held just below factory-calibrated CGMs and the 365 by its heavier calibration.
55
Why this empowerment score. Excellent open sharing (Tidepool/Glooko/Apple Health), but surgical insertion, calibration, and a prescription hold empowerment mid-range.
48
Why this everyday score. Six months between sensors is low-maintenance, but surgery and twice-daily early calibration weigh on everyday use.
Latest news
Reviews & coverage
Reviewers value the long-duration implant for people tired of frequent sensor swaps, with solid accuracy in studies. The trade-offs remain the clinical procedure to place it and the adhesive transmitter worn over the site.
Summary is a draft synthesis of public coverage, not an endorsement. Links open a search of each outlet.
Reddit communities
Independent user communities where this device (or its category) is discussed.
Get it · manuals & support
Draft profile · public-source review, June 2026 · scores describe direction and degree, not buying advice. News, links, and prices change — verify with the manufacturer. Image is representative.